

Step by step towards Global Digital Child Care

Liesbeth Siderius, Rare Care World, The Netherlands

Sahan Damsiri Perera, University of Colombo, Colombo, Sri Lanka



EPA/ ECPCP Antalya April 20th 2024


Digital Modelling of Primary Child Health

- Illustrative cases from **The WHO Pocket Book on Primary health care for Children and Adolescents** (WHO Europe, 2022)
- Proof of concept for a comprehensive implementation guide that harnesses the **digital terminologies** and **HL7/FHIR standards**
- Facilitating the seamless integration of **WHO's quality healthcare standards** into diverse primary care environments for children and adolescents.



World Health Organization

Digital Modelling of Primary Child Health



<https://www.who.int/europe/publications/i/item/9789289057622>

Introduction


Dissemination and generation of knowledge on complex diseases in children depends on the **availability** and **interoperability of primary child health data**.

Method

Identify structured set of interoperable international **data terminologies** such as the International Classification of Diseases (ICD) and International Classification of Function (ICF) as well as the numerical Logical Observation Identifiers Names and Codes (LOINC).

International terminologies as a tool for interoperability in child health

Towards a Global Integrated Digital Preventive Child Health Model



One code = One meaning

ICPC: International Classification of Primary Care

HPO: Human Phenotype Ontology

LOINC Standard for identifying health measurements, observations, and documents

ICD: International Classification of Diseases

ICF: International Classification of function


ATC: Anatomical Therapeutic Chemical Classification System

ORPHA: Classification of rare diseases

OMIM: Catalog of Human Genes and Genetic Disorders

Use of terminologies enables semantic interoperability between systems using HL7 CDA and FHIR


Title “Digital child health: opportunities and obstacles”, by Liesbeth Siderius*, Sahan Damsiri Perera, Lars Gelander, Lina Jankauskaite, Manuel Katz, Arunas Valiulis, Adamos A. Hadjipanayis, Laura Realí and Zachi Grossman, published in “Frontiers in Pediatrics-Children and Health”.



Author Figure S.D. Perera, University Colombo, Sri Lanka



World Health Organization



Universal Health Coverage, leave no child behind

The health information system ensures the collection, analysis and use of data to ensure early, appropriate action **to improve the care of every child**

3.2 Well-child visit: birth – 72 hours

Most children will be seen in hospital for these visits; if not, they ought to be seen by the primary care provider within 24 hours of birth and again at 48–72 hours.

- Look for congenital diseases and jaundice
- Support caregivers.

History

- Problems during pregnancy, e.g. diabetes, medications, substance abuse, acute or chronic infections, mental or social stress, abnormal test results, e.g. positive group B Streptococcus, HIV, hepatitis B
- Mode of delivery and problems during or after birth
- Congenital disorders in the family, e.g. hip problems
- Hip dysplasia risk factors, e.g. twin pregnancy, breech position
- Problems passing meconium and urine

Results

data terminologies

- achondroplasia
- thalassemia
- Shwachman Diamond syndrome



Maternal Achondroplasia

CARE AND PHYSICAL EXAMINATION OF THE NEWBORN AFTER BIRTH

Vitamin K

- 1 mg vitamin K IM within the first hour of birth (during initial breast-feeding while the infant is in skin-to-skin contact with the mother) **or**
- 3 doses of 2 mg vitamin K orally: at birth, at 4 to 6 days, and at 4 to 6 weeks.
- Preterm newborns should receive a lower dose 0.4 mg/kg IM.

Vitamin D

- Daily dose of 400 IU vitamin D starting within days after birth for at least the first 12 months of life.

History

Take a thorough medical history including:

- **Baby's progress since birth:** any parental concerns, feeding, problems in passing urine (usually within 24 hours of birth) and meconium (usually within 48 hours of birth) (p. 150).
- **Maternal history:** age, social background, chronic maternal diseases, medical treatments and drugs, recreational drugs including alcohol and smoking.
- **Family history:** father's age, genetic conditions, consanguinity of parents, previous pregnancies and health of siblings.
- **Present pregnancy:** medical conditions that may have influenced the pregnancy (e.g. gestational diabetes), complications, screening tests and special diagnostic procedures, exposure to maternal infectious diseases such as hepatitis B (p. 168), HIV (p. 167), cytomegalovirus (p. 163), syphilis (p. 164) or toxoplasmosis (p. 165) during pregnancy or delivery.
- **Labour and delivery:** mode of delivery, length of labour, signs of fetal distress, drugs and/or anaesthesia given, APGAR score (p. 24).
- **Risk factors for neonatal infections:**
 - Premature rupture of membranes (> 18 h before delivery)
 - Maternal fever > 38 °C before delivery or during labour
 - Foul-smelling or purulent (chorioamnionitis) amniotic fluid
 - Maternal colonization with Group B streptococcus
 - Preterm delivery.

5. NEWBORN HEALTH

Pregnant woman visit PCH at 22 weeks pregnancy

Mother : Diagnosed with **achondroplasia** (data academic hospital)

Pregnancy & Fetus : Short femur by ultra sound observations at 22 weeks of pregnancy

PCH officer considers child has achondroplasia & Refer to academic hospital

Child at birth : **Macrocephaly and short stature** at birth


After birth:

Child head circumference, body length and weight are followed according to achondroplasia growth curves

Maternal Achondroplasia

Integration in electronic health records

Date Flow HL7



Terminologies

Femur Length US	LOINC	11963-6
Head Occipital-frontal circumference by Tape measure	LOINC	8287-5
Birth weight Measured	LOINC	8339-4
Body height Measured --at birth	LOINC	89269-5
Achondroplasia	ICD 10	Q77.4

Digital language JSON


```
{ "resourceType": "Observation", "id": "cfsb1704636128883", "status": "final",
  "code": { "coding": [ { "code": "3141-9", "system": "http://loinc.org", "display": "Body weight Measured" } ] },
  "valueQuantity": { "value": 10, "unit": "kg" },
  "interpretation": [ { "coding": [ { "code": "L", "system": "http://terminology.hl7.org/CodeSystem/v3-ObservationInterpretation", "display": "Low" } ] } ],
  "subject": { "reference": "cfsb1704507726008" },
  "effectiveDateTime": "2024-01-01T00:00:00.000Z" }
```




Maternal Achondroplasia

Real life data


LOINC 29463-7 Body weight




LOINC 8302-2 Body height



LOINC 8287-5 Head Occipital-frontal circumference by Tape measure



Hydrocephalus Risk



New Treatment

Achondroplasia-growth curve at each primary care visit

The company will price the treatment at roughly \$300,000 per year



A four Month Old Child at PHC Visit In Sri Lanka

7.14 Thalassaemia

Thalassaemias are a group of autosomal-recessive hereditary blood disorders, which are characterized by defective haemoglobin chains. Based on the defective globin chain, they are classified as either α - or β -thalassaemia. They are more common in Mediterranean countries but immigration has led to wider distribution.

History

Assess for risk factors:

- Family history of α - or β -thalassaemia
- History of recurrent need for transfusions in patient or family member
- Prenatal diagnosis declined by the pregnant woman or couple at risk of thalassaemia carrier status
- Ethnic background from sub-Saharan Africa, Mediterranean and Arabian peninsula, Southeast Asia, Indian subcontinent.

Symptoms

Symptoms and timing of clinical manifestation depend on the type of thalassaemia. Severity of symptoms ranges from asymptomatic minor forms or silent carrier status to death in utero in severe forms (alpha-thalassaemia major).

Symptoms include:

- Pallor
- Abdominal distension
- Failure to thrive, poor feeding, decreased activity, lethargy
- Enlarged liver and spleen
- Jaundice
- Symptoms of gallstones: sudden intense pain in upper right abdomen
- Skeletal deformities: large head with frontal and parietal bossing, "chipmunk" facies, misaligned teeth.

Investigations

- Full blood count: microcytic hypochromic anaemia
- Ferritin
- Further investigations: peripheral smear, DNA analysis, X-ray for skeletal deformities.

PCH

Vaccination: DTP

Physical exam: **Pale | Large spleen and liver**

Laboratory test : Hemoglobine | Microcysis red blood cells


Referral to Thalassemia clinic

Parents are advised about routine vaccinations

Cascade Screening of Family

Diagnosis : Beta Thalassemia

NATIONAL IMMUNIZATION SCHEDULE - SRI LANKA NATIONAL IMMUNIZATION PROGRAMME




FIRST YEAR OF LIFE

0-4 Weeks	BCG	Preferably within 24 hours of birth (Before leaving hospital) If a scar is not present 2 nd dose could be offered after 6months, upto 5 years
On completion of :		
2 Months	OPV & Pentavalent (DTP-HepB-Hib) (1 st dose) fIPV (Fractional IPV) (1 st dose)	For a defaulter or for an un-vaccinated child minimum of 6-8 weeks gap between doses is adequate
4 Months	OPV & Pentavalent (DTP-HepB-Hib) (2 nd dose) fIPV (Fractional IPV) (2 nd dose)	
6 Months	OPV & Pentavalent (DTP-HepB-Hib) (3 rd dose)	
9 Months	MMR (1 st Dose)	


Beta Thalassemia

Integration in electronic health records

Date Flow HL7



FHIR



Digital Language JSON

```
{ "resourceType": "Practitioner", "id": "cfsb1704509045558", "name": [ { "text": "Doctor  
Practitioner", "given": [ "Doctor" ], "family": [ "Practitioner" ] }, { "system": "email", "value": "xxx@xxx.com", "use": "work" }, { "system": "phone", "value": "0771111111", "use": "work" } ], "address": [ { "text": "No x, Stree x, City  
X", "use": "work", "type": "both", "line": [ "No X" ], "city": "Clty X", "country": "XXX" } ] }
```

Terminologies


diphtheria-poliomyelitis-tetanus	ATC	J07CA01
Pallor	SNOMED CT	1237486008
Hepatomegaly	SNOMED CT	80515008
Splenomegaly	SNOMED CT	16294009
Haemoglobin concentration in blood	LOINC	718-7
Microcytes in blood film	LOINC	741-9
Feeding disorder of infancy and childhood	ICD 10	F98.2
Beta Thalassaemia	ICD 10	D56.1



World Health Organization

Beta Thalassemia

Carrier rate of β -thalassemia in endemic countries. Data taken from the global burden of disease collaborative network.



Front. Hematol., 20 June 2023

Sec. Red Cells, Iron and Erythropoiesis Volume 2 - 2023 | <https://doi.org/10.3389/frhem.2023.1187681>

From Feature to Medical Guideline


Feature

- Fatty Stool
- Failure to thrive
- Common infections

Shwachman Diamond

Syndrome- *Management*

- Pancreas insufficiency
- Neutropenia
- Skeletal Dysplasia
- Autisme like



Failure to thrive

- HP:0001531
- LOINC:42819-3 Failure to thrive [CCC]
- ICPC: T10

Fatty Stool


- LOINC 16142-2 Fat [Mass/time] in 24 hour Stool

Pancreas insufficiencie

- ICD -10 K86.81

Shwachman Diamond S
ORPHA:811
OMIM# 260400

Cystic Fybrosis
ORPHA:586
OMIM # 21970




ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Issue: Annals Meeting Reports

Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome

Yigal Dror,¹ Jean Donadieu,² Jutta Kogelmeier,³ John Dodge,⁴ Sanna Toiviainen-Salo,⁵ Outi Makitie,⁵ Elizabeth Kerr,¹ Cornelia Zeidler,⁶ Akiko Shimamura,⁷ Neil Shah,³ Marco Cipolli,⁸ Taco Kuijpers,⁹ Peter Durie,¹ Johanna Rommens,¹ Liesbeth Siderius,¹⁰ and Johnson M. Liu¹¹

Patient Information	Primary Care	Diagnosis Collaborative care	Social Services
www.shwachman.nl https://rarecare.world	Growth retardation Recurrent infections (LOINC)	Guideline SDS (Orphanetcode; SNOMED, ATC e.a.)	Recurrent illness Fatigue, Short (ICF-CY; ISO 9999)

Stichting Shwachman syndroom Support Holland



Terminologies enable semantic interoperability in health information exchange standards systems using HL7 CDA and FHIR



This page is part of the FHIR Specification (v5.0.0: R5 - STU). This is the current published version. For a full list of available versions, see the [Directory of published versions](#).
Page versions: **R5** [R4B](#) [R4](#) [R3](#) [R2](#)

3.2.0 RESTful API

[FHIR Infrastructure](#) [Work Group](#)

Maturity Level: Normative

Standards Status: Normative

FHIR is described as a 'RESTful' specification based on common industry level use of the term REST. In practice, FHIR only supports Level 2 of the [REST Maturity model](#) as part of the core specification, though full Level 3 conformance is possible through the use of [extensions](#). Because FHIR is a standard, it relies on the standardization of resource structures and interfaces. This may be considered a violation of REST principles but is key to ensuring consistent interoperability across diverse systems.

For each "resource type" the same set of interactions are defined which can be used to manage the resources in a highly granular fashion. Applications claiming conformance to this framework claim to be conformant to "RESTful FHIR" (see [Conformance](#)).

Note that in this RESTful framework, transactions are performed directly on the server resource using an HTTP request/response. The API does not directly address authentication, authorization, and audit collection - for further information, see the [Security Page](#). All the interactions are all described for synchronous use, and an [Asynchronous use pattern](#) is also defined.

The API describes the FHIR resources as a set of operations (known as "interactions") on resources where individual resource instances are managed in collections by their type. Servers can choose which of these interactions are made available and which resource types they support. Servers SHALL provide a [Capability Statement](#) that specifies which interactions and resources are supported.

In addition to a number of [General Considerations](#) this page defines the following interactions:

Instance Level Interactions

Open Access FHIR RESTfull API Library



adolescents

GUIDELINES FOR HEALTH PROMOTION,
DISEASE PREVENTION AND MANAGEMENT

Mother and Child Health

- Growth & Development
- Conditions



PEDIATRIC
ENDOCRINOLOGY

Computable clinical guidelines

- Thalassemia
- Shwachman Diamond Syndrome



Vaccines

Immunizations


- Vaccination schemes



Person in a chair

Social Support

- ICF
- ISO 9999



Conclusion

- **Evidence based guidelines** are the basis of global child health care
- **Clinical data** points derived from guidelines by clinicians serve as interoperable **terminologies**
- Care delivery is 'translated' into **digital language** as JSON
- FHIR enables semantic interoperability in health information exchange standards systems for **clinical and administrative content**
- A defined FHIR profile can be offered as **application programming interface** (API) to enable two or more computer programs to communicate with each other




Title “Digital child health: opportunities and obstacles”, by Liesbeth Siderius*, Sahan Damsiri Perera, Lars Gelander, Lina Jankauskaite, Manuel Katz, Arunas Valiulis, Adamos A. Hadjipanayis, Laura Realí and Zachi Grossman, published in “Frontiers in Pediatrics-Children and Health”.

Front. Pediatr., 22 December 2023

Sec. Children and Health

Volume 11 - 2023 | <https://doi.org/10.3389/fped.2023.1264829>





Thank

- European Pediatric Rare Disease Network
John Dodge, U.K.
Lali Margvelashvili, Georgia
Velibor Tasic, N- Macedonia
David Neubauer, Slovenia
Arunas Valiulis, Lithuania
Lina Jankauskaite, Lithuania
Jola Wierzba, Poland
Jernej Zavrsnik, Slovenia
- Consensus in Pediatrics and Child Health
Manual Katz, Israel
- Forum Rare Diseases, Sri Lankan Pediatric Society
Anjan Bhattacharya, ICF expert India
Sahan Damsiri Perera, IT Expert, Sri Lanka
Marc de Graauw, IT Expert, Netherlands
Martin Postma, IT Expert, Netherlands
- People with a rare condition and their families

Siderius, L., Neubauer, D., Bhattacharya, A., Altorjai, P., Margvelashvili, L., Lamabadusuriya, S., Wierzba, J., Mazur, A., Albrecht, P., and Tasic, V. (2021). Universal Health Coverage "Leave No Child Behind". *Pediatrica Polska - Polish Journal of Paediatrics*, 96(1), pp.1-6.
<https://doi.org/10.5114/polp.2021.104822>



e.siderius@kpnplanet.nl

Stichting Shwachman syndroom



Support Holland